Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments: 2010-2025

Historic Short-term Investments for Vanda Pharmaceuticals (VNDA) over the last 14 years, with Sep 2025 value amounting to $223.7 million.

  • Vanda Pharmaceuticals' Short-term Investments fell 18.87% to $223.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.7 million, marking a year-over-year decrease of 18.87%. This contributed to the annual value of $272.3 million for FY2024, which is 7.88% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Short-term Investments stood at $223.7 million, which was down 8.52% from $244.6 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Short-term Investments peaked at $405.4 million during Q3 2022, and registered a low of $147.3 million during Q1 2023.
  • Over the past 3 years, Vanda Pharmaceuticals' median Short-term Investments value was $269.0 million (recorded in 2024), while the average stood at $258.6 million.
  • In the last 5 years, Vanda Pharmaceuticals' Short-term Investments tumbled by 59.99% in 2023 and then surged by 82.58% in 2024.
  • Vanda Pharmaceuticals' Short-term Investments (Quarterly) stood at $380.7 million in 2021, then declined by 12.85% to $331.8 million in 2022, then fell by 23.92% to $252.4 million in 2023, then increased by 7.88% to $272.3 million in 2024, then decreased by 18.87% to $223.7 million in 2025.
  • Its Short-term Investments stands at $223.7 million for Q3 2025, versus $244.6 million for Q2 2025 and $229.1 million for Q1 2025.